Lineage Cell Therapeutics’ (LCTX) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) in a report issued on Tuesday morning,Benzinga reports. HC Wainwright currently has a $9.00 price objective on the stock.

Several other research firms have also weighed in on LCTX. D. Boral Capital lowered their target price on shares of Lineage Cell Therapeutics from $3.00 to $2.00 and set a “buy” rating for the company in a research note on Tuesday. Maxim Group decreased their price target on shares of Lineage Cell Therapeutics from $5.00 to $3.00 and set a “buy” rating for the company in a report on Friday, January 10th.

Lineage Cell Therapeutics Stock Up 6.9 %

Shares of LCTX stock opened at $0.69 on Tuesday. The firm has a market cap of $150.99 million, a price-to-earnings ratio of -5.71 and a beta of 1.21. Lineage Cell Therapeutics has a 1-year low of $0.48 and a 1-year high of $1.61.

Hedge Funds Weigh In On Lineage Cell Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Fort Sheridan Advisors LLC boosted its position in shares of Lineage Cell Therapeutics by 71.5% during the 4th quarter. Fort Sheridan Advisors LLC now owns 55,177 shares of the company’s stock valued at $28,000 after purchasing an additional 23,000 shares in the last quarter. Atria Wealth Solutions Inc. acquired a new stake in Lineage Cell Therapeutics during the fourth quarter valued at approximately $29,000. HighTower Advisors LLC boosted its holdings in Lineage Cell Therapeutics by 49.5% during the fourth quarter. HighTower Advisors LLC now owns 57,706 shares of the company’s stock worth $29,000 after buying an additional 19,100 shares in the last quarter. SG Americas Securities LLC grew its position in Lineage Cell Therapeutics by 35.5% in the fourth quarter. SG Americas Securities LLC now owns 68,973 shares of the company’s stock worth $35,000 after buying an additional 18,053 shares during the last quarter. Finally, Wells Fargo & Company MN increased its holdings in shares of Lineage Cell Therapeutics by 33.0% in the fourth quarter. Wells Fargo & Company MN now owns 94,894 shares of the company’s stock valued at $48,000 after buying an additional 23,527 shares in the last quarter. 62.47% of the stock is owned by institutional investors.

Lineage Cell Therapeutics Company Profile

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.